Long-term results in patients with idiopathic dilated cardiomyopathy after weaning from left ventricular assist

Michael Dandel1, Yuguo Weng, Henryk Siniawski

  • 1Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany. dandel@dhzb.de

Circulation
|September 15, 2005
PubMed

Insights

Weaning patients with idiopathic dilated cardiomyopathy from left ventricular assist devices (LVADs) is a viable option with good long-term outcomes. Echocardiography reliably predicts cardiac recovery and stability after LVAD explantation.

Area of Science:

  • Cardiology
  • Medical Devices
  • Heart Failure Research

Background:

  • Left ventricular assist devices (LVADs) have been used to treat idiopathic dilated cardiomyopathy (IDCM).
  • Since 1995, 32 IDCM patients have been successfully weaned from LVADs in this department.
  • Echocardiography during "off-pump" trials was crucial for weaning decisions.

Purpose of the Study:

  • To assess the reliability of weaning criteria for IDCM patients based on long-term results.
  • To evaluate the long-term cardiac function and survival rates after LVAD explantation in IDCM patients.
  • To determine the predictive value of echocardiographic data for long-term cardiac stability post-weaning.

Main Methods:

  • Evaluation of 32 IDCM patients weaned between March 1995 and March 2004.
  • Assessment of cardiac function preservation and survival post-LVAD explantation.
  • Review of echocardiographic data (LV end-diastolic diameter, LVEF) and patient history (HF duration) to identify risk factors for recurrence.

Main Results:

  • Survival rate at 5 years post-explantation was 78.3%.
  • Heart failure (HF) recurred in 31.3% within 3 years; most were successfully transplanted.
  • Risk factors for early HF recurrence included LV end-diastolic diameter >55 mm, LVEF <45%, and HF history ≥5 years.
  • Patients with no risk factors showed no recurrence; those with ≥2 risk factors had early recurrence.
  • Echocardiographic changes (LVEF decrease) were noted within the first month in patients with HF recurrence.

Conclusions:

  • LVAD weaning is a clinical option for selected IDCM patients with demonstrated cardiac recovery.
  • Off-pump echocardiographic parameters are reliable for assessing LV recovery and predicting long-term stability.
  • Consider LVAD weaning in IDCM patients showing cardiac recovery post-implantation.
Abstract

Related Concept Videos

Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...